| scholarly article | Q13442814 |
| P50 | author | Satdarshan P Monga | Q88533584 |
| P2093 | author name string | Xin Chen | |
| Rong Zhang | |||
| Michael Oertel | |||
| Minakshi Poddar | |||
| Shanthi Ganesh | |||
| Junyan Tao | |||
| Sucha Singh | |||
| Marc Abrams | |||
| Emily Xu | |||
| P2860 | cites work | The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 |
| β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis | Q28087660 | ||
| Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis | Q28246808 | ||
| Ras oncogenes: split personalities | Q29615405 | ||
| COSMIC: exploring the world's knowledge of somatic mutations in human cancer | Q29615725 | ||
| Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer | Q30746254 | ||
| Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma | Q33706930 | ||
| Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo | Q34268708 | ||
| Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model | Q34989670 | ||
| SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice | Q35273519 | ||
| Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice | Q35698850 | ||
| Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Q35842729 | ||
| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Q36104399 | ||
| Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. | Q36330223 | ||
| Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma | Q36547263 | ||
| Postponing the Hypoglycemic Response to Partial Hepatectomy Delays Mouse Liver Regeneration | Q36753754 | ||
| Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin | Q37231321 | ||
| Beta-catenin regulates vitamin C biosynthesis and cell survival in murine liver | Q37459941 | ||
| Hydrodynamic transfection for generation of novel mouse models for liver cancer research | Q38183539 | ||
| Nanotechnological carriers for cancer chemotherapy: the state of the art. | Q38319607 | ||
| The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications | Q38400354 | ||
| Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. | Q38534459 | ||
| Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts | Q38970692 | ||
| β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma | Q38993024 | ||
| AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/ | Q39459058 | ||
| L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells. | Q39491727 | ||
| The global decrease in cancer mortality: trends and disparities. | Q40070789 | ||
| Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma | Q42045560 | ||
| Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. | Q42182074 | ||
| Conditional deletion of beta-catenin reveals its role in liver growth and regeneration | Q42504022 | ||
| Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin. | Q42711666 | ||
| New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism | Q44226601 | ||
| Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. | Q53347351 | ||
| Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas | Q80238304 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1581-1599 | |
| P577 | publication date | 2017-02-06 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice | |
| P478 | volume | 65 |
| Q64996715 | Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice. |
| Q88072465 | Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration |
| Q90569988 | CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma |
| Q49952320 | Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. |
| Q97426639 | Hepatoblastoma: current knowledge and promises from preclinical studies |
| Q100533943 | Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis |
| Q49433039 | Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling |
| Q64097554 | Promotion of growth factor signaling as a critical function of β-catenin during HCC progression |
| Q64100898 | Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer |
| Q50156185 | The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model |
| Q91754947 | The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance |
| Q52331269 | The transcription factor 7 like 2‑binding protein TIP5 activates β‑catenin/transcription factor signaling in hepatocellular carcinoma. |
| Q42513643 | Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer. |
| Q52782089 | WNTing no RASt for hepatocellular carcinoma. |
| Q93209106 | Wnt-β-catenin signalling in liver development, health and disease |
| Q50070375 | Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology |
| Q91833707 | β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis |
| Q49547317 | β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models |
Search more.